(Q37717088)

22 August 2017

1 reference

title

Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens (English)

1 reference

22 August 2017

1 reference

0 references

1 reference

acute myeloid leukemia

1 reference

W Hiddemann

1

1 reference

22 August 2017

publication date

1 April 1991

1 reference

22 August 2017

1 reference

22 August 2017

volume

62

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

119-128

1 reference

In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia.

22 August 2017

cites work

1 reference

12 December 2020

Altered sensitivity to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate of DNA polymerase alpha from leukemic blasts of acute lymphoblastic leukemia

1 reference

12 December 2020

Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.

1 reference

12 December 2020

Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized f

1 reference

12 December 2020

Metabolism of ara-C by blast cells from patients with ANLL.

1 reference

12 December 2020

COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE.

1 reference

12 December 2020

Experience with Intermediate and High Dose Cytosine Arabinoside in Refractory Acute Leukaemia

1 reference

12 December 2020

Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia

1 reference

12 December 2020

High dose cytarabine: a review

1 reference

12 December 2020

Acute myelogenous leukemia: recent advances in therapy

1 reference

12 December 2020

Chemotherapy versus transplantation in acute leukaemia

1 reference

12 December 2020

The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture

1 reference

12 December 2020

Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells

1 reference

12 December 2020

Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878)

1 reference

12 December 2020

High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results

1 reference

12 December 2020

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

1 reference

12 December 2020

Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans

1 reference

12 December 2020

Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine

1 reference

12 December 2020

Cytidine deaminase and the development of resistance to arabinosyl cytosine.

1 reference

12 December 2020

Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5'-triphosphate of 9-beta-d-arabinofuranoxyladenine

1 reference

12 December 2020

Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment

1 reference

12 December 2020

High-dose cytosine arabinoside in the treatment of resistant acute leukemia.

1 reference

12 December 2020

In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia

1 reference

12 December 2020

High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma

1 reference

12 December 2020

Regulation of the cytidine phospholipid pathways in human cancer cells and effects of 1-beta-D-arabinofuranosylcytosine: a noninvasive 31P nuclear magnetic resonance study

1 reference

12 December 2020

Cytosine arabinoside influx and nucleoside transport sites in acute leukemia

1 reference

12 December 2020

Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.

1 reference

12 December 2020

Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity

1 reference

12 December 2020

In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia

1 reference

12 December 2020

Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5'-triphosphate

1 reference

12 December 2020

High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contributions to outcome of clinical and laboratory attributes

1 reference

12 December 2020

Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia.

1 reference

12 December 2020

High-dose cytosine arabinoside: pharmacological and clinical aspects

1 reference

12 December 2020

Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.

1 reference

12 December 2020

Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: the Leyden experience and review of the literature

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia.

1 reference

12 December 2020

High dose cytosine arabinoside in the management of refractory acute leukaemia.

1 reference

12 December 2020

Megaloblastosis produced by a cytosine antagonist, 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C)

1 reference

12 December 2020

Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy

1 reference

12 December 2020

Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines

1 reference

12 December 2020

Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells

1 reference

12 December 2020

A phase I-II study of combination therapy with thymidine and cytosine arabinoside

1 reference

12 December 2020

Effect of cytosine arabinoside 5'-triphosphate on mammalian DNA polymerase

1 reference

12 December 2020

Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients

1 reference

12 December 2020

Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia

1 reference

12 December 2020

Clinical pharmacology of l-β-D-arabinofuranosyl cytosine

1 reference

12 December 2020

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

1 reference

12 December 2020

Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.

1 reference

12 December 2020

High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.

1 reference

12 December 2020

High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.

1 reference

12 December 2020

Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside

1 reference

12 December 2020

Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo

1 reference

12 December 2020

Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity

1 reference

12 December 2020

Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells.

1 reference

12 December 2020

Pharmacologically directed ara-C therapy for refractory leukemia.

1 reference

12 December 2020

The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse

1 reference

12 December 2020

Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia

1 reference

12 December 2020

Progress in the treatment of adults with acute leukemia: review of regimens containing cytarabine studied by the Southwest Oncology Group

1 reference

12 December 2020

Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid

1 reference

12 December 2020

Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells

1 reference

12 December 2020

Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside.

1 reference

12 December 2020

Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia.

1 reference

12 December 2020

High-dose cytosine arabinoside for acute nonlymphocytic leukemia.

1 reference

12 December 2020

Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion

1 reference

12 December 2020

Advances in the Treatment of Acute Myelogenous Leukemia

1 reference

12 December 2020

High-dose cytosine arabinoside therapy for refractory leukemia

1 reference

12 December 2020

Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells

1 reference

12 December 2020

Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia

1 reference

12 December 2020

1 reference

12 December 2020

Inhibition of glycoprotein and glycolipid synthesis in hamster embryo cells by cytosine arabinoside and hydroxyurea

1 reference

12 December 2020

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy

1 reference

12 December 2020

High-dose cytosine arabinoside and daunomycin as primary therapy for adults with acute nonlymphoblastic leukemia: a pilot study

1 reference

12 December 2020

Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules

1 reference

12 December 2020

Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B

1 reference

12 December 2020

Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.

1 reference

12 December 2020

Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase

1 reference

12 December 2020

Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse

1 reference

12 December 2020

Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside

1 reference

12 December 2020

Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults

1 reference

12 December 2020

Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C

1 reference

12 December 2020

High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison

1 reference

12 December 2020

Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).

1 reference

12 December 2020

Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA

1 reference

12 December 2020

Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy

1 reference

12 December 2020

Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia

1 reference

12 December 2020

Activity of cytosine arabinoside (NSC-63878) in a spectrum of rodent tumors

1 reference

12 December 2020

Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia

1 reference

12 December 2020

A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.

1 reference

12 December 2020

Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group

1 reference

12 December 2020

Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells.

1 reference

12 December 2020

Antitumor activity of 1-beta-D-arainofuranosylcytosine hydrochloride

1 reference

12 December 2020

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

1 reference

12 December 2020

Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.

1 reference

12 December 2020

Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia

1 reference

12 December 2020

Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review

1 reference

12 December 2020

Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside

1 reference

12 December 2020

Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside

1 reference

12 December 2020

Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation

1 reference

12 December 2020

High-dose cytosine arabinoside: clinical response to therapy in acute leukemia

1 reference

12 December 2020

Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside.

1 reference

12 December 2020

Cerebellar toxicity with high-dose cytosine arabinoside

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01702925

1 reference

release_474zjg2a4zh4zmjdv777v7stdy

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/474zjg2a4zh4zmjdv777v7stdy

24 November 2022

mapped directly with Wikidata item

1 reference